Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vascular smooth muscle cell (VSMC) relaxation via nitric oxide (NO) release is a fundamental physiological process that regulates vascular tone and blood pressure. This mechanism involves the production and release of NO, which acts as a potent vasodilator by inducing relaxation in the smooth muscle cells lining blood vessels. NO activates soluble guanylate cyclase (sGC) in VSMCs, leading to increased production of cGMP. cGMP activates protein kinase G (PKG), which phosphorylates target proteins that reduce intracellular calcium concentration and inhibit myosin light chain kinase activity, leading to smooth muscle relaxation.
NO donors increase intracellular cGMP levels leading to activation of protein kinase G, which phosphorylates target proteins that reduce intracellular calcium concentration and inhibit myosin light chain kinase activity, ultimately causing smooth muscle relaxation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vascular Smooth Muscle Cell Relaxation via Nitric Oxide Release (None).